Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn Injuries
Sponsor: University of Tennessee
Summary
Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2026-02-16
Completion Date
2027-02-28
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
Cefiderocol
Cefiderocol will be prescribed according to indication and estimated renal function as either 2g over 3 hours dosed either every 6 or 8 hours.
Locations (1)
Regional One Health
Memphis, Tennessee, United States